In June 2020, the Federal Government introduced several regulatory changes in relation to the prescribing of opioids for the management of pain.

These changes applied to immediate release and sustained release versions of; buprenorphine, codeine, fentanyl, hydromorphone, methadone, morphine, oxycodone, tapentadol, tramadol and included smaller pack sizes and changes to the authority required for opioids to be subsidised.

More than a year since the reforms were introduced, Painaustralia would like to hear from consumers living with chronic pain to further understand what impact these changes may have had.

We would like to hear about your experience in the past 18 months, whether there have been any barriers in accessing treatment and how you are coping with any challenges you may have subsequently faced.

Question Title

* 1. Your age

Question Title

* 2. Your gender

Question Title

* 3. State

Question Title

* 4. Your postcode

Question Title

* 5. What is your chronic pain condition? Select all that apply.

Question Title

* 6. Have you ever used an opioid medication to manage your chronic pain?

Question Title

* 7. Do you currently use opioid medication for your chronic pain?

0 of 21 answered
 

T